212 related articles for article (PubMed ID: 21996985)
1. Tissue-based molecular markers for renal cell carcinoma.
Rink M; Chun FK; Robinson B; Sun M; Karakiewicz PI; Bensalah K; Fisch M; Scherr DS; Lee RK; Margulis V; Shariat SF
Minerva Urol Nefrol; 2011 Dec; 63(4):293-308. PubMed ID: 21996985
[TBL] [Abstract][Full Text] [Related]
2. Identification and validation of novel prognostic markers in Renal Cell Carcinoma.
Rabjerg M
Dan Med J; 2017 Oct; 64(10):. PubMed ID: 28975890
[TBL] [Abstract][Full Text] [Related]
3. Carbonic anhydrase IX in renal cell carcinoma: implications for prognosis, diagnosis, and therapy.
Stillebroer AB; Mulders PF; Boerman OC; Oyen WJ; Oosterwijk E
Eur Urol; 2010 Jul; 58(1):75-83. PubMed ID: 20359812
[TBL] [Abstract][Full Text] [Related]
4. Hypoxia-inducible factor 1 alpha in clear cell renal cell carcinoma.
Klatte T; Seligson DB; Riggs SB; Leppert JT; Berkman MK; Kleid MD; Yu H; Kabbinavar FF; Pantuck AJ; Belldegrun AS
Clin Cancer Res; 2007 Dec; 13(24):7388-93. PubMed ID: 18094421
[TBL] [Abstract][Full Text] [Related]
5. Vimentin over-expression and carbonic anhydrase IX under-expression are independent predictors of recurrence, specific and overall survival in non-metastatic clear-cell renal carcinoma: a validation study.
Ingels A; Hew M; Algaba F; de Boer OJ; van Moorselaar RJ; Horenblas S; Zondervan P; de la Rosette JJ; Pilar Laguna Pes M
World J Urol; 2017 Jan; 35(1):81-87. PubMed ID: 27207480
[TBL] [Abstract][Full Text] [Related]
6. Biomarkers in renal cell carcinoma.
McGuire BB; Fitzpatrick JM
Curr Opin Urol; 2009 Sep; 19(5):441-6. PubMed ID: 19584732
[TBL] [Abstract][Full Text] [Related]
7. Current status and future directions of molecular markers in renal cell carcinoma.
Rini BI
Curr Opin Urol; 2006 Sep; 16(5):332-6. PubMed ID: 16905977
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of the co-expression of carbonic anhydrase IX and vascular endothelial growth factor in patients with clear cell renal cell carcinoma.
Phuoc NB; Ehara H; Gotoh T; Nakano M; Kamei S; Deguchi T; Hirose Y
Oncol Rep; 2008 Sep; 20(3):525-30. PubMed ID: 18695901
[TBL] [Abstract][Full Text] [Related]
9. [Prognostic factors in renal cell carcinoma].
Wen JJ; Zhou XJ
Zhonghua Bing Li Xue Za Zhi; 2013 Dec; 42(12):850-3. PubMed ID: 24507112
[No Abstract] [Full Text] [Related]
10. Pathobiology, prognosis, and targeted therapy for renal cell carcinoma: exploiting the hypoxia-induced pathway.
Pantuck AJ; Zeng G; Belldegrun AS; Figlin RA
Clin Cancer Res; 2003 Oct; 9(13):4641-52. PubMed ID: 14581333
[TBL] [Abstract][Full Text] [Related]
11. Prognostic factors in patients with advanced renal cell carcinoma.
Muriel López C; Esteban E; Berros JP; Pardo P; Astudillo A; Izquierdo M; Crespo G; Sanmamed M; Fonseca PJ; Martínez-Camblor P
Clin Genitourin Cancer; 2012 Dec; 10(4):262-70. PubMed ID: 22959659
[TBL] [Abstract][Full Text] [Related]
12. Immunohistochemical Panel for Differentiating Renal Cell Carcinoma with Clear and Papillary Features.
Alshenawy HA
Pathol Oncol Res; 2015 Sep; 21(4):893-9. PubMed ID: 25712789
[TBL] [Abstract][Full Text] [Related]
13. Clinical and molecular prognostic factors in renal cell carcinoma: what we know so far.
Tang PA; Vickers MM; Heng DY
Hematol Oncol Clin North Am; 2011 Aug; 25(4):871-91. PubMed ID: 21763972
[TBL] [Abstract][Full Text] [Related]
14. Prognostic and predictive biomarkers in renal cell carcinoma.
Vickers MM; Heng DY
Target Oncol; 2010 Jun; 5(2):85-94. PubMed ID: 20582732
[TBL] [Abstract][Full Text] [Related]
15. Genetic pathways involved in carcinogenesis of clear cell renal cell carcinoma: genomics towards personalized medicine.
Audenet F; Yates DR; Cancel-Tassin G; Cussenot O; Rouprêt M
BJU Int; 2012 Jun; 109(12):1864-70. PubMed ID: 22035299
[TBL] [Abstract][Full Text] [Related]
16. Prognostic role of tumor necrosis, microvessel density, vascular endothelial growth factor and hypoxia inducible factor-1alpha in patients with clear cell renal carcinoma after radical nephrectomy in a long term follow-up.
Minardi D; Lucarini G; Filosa A; Milanese G; Zizzi A; Di Primio R; Montironi R; Muzzonigro G
Int J Immunopathol Pharmacol; 2008; 21(2):447-55. PubMed ID: 18547492
[TBL] [Abstract][Full Text] [Related]
17. Expression of molecular markers associated with the mammalian target of rapamycin pathway in nonmetastatic renal cell carcinoma: Effect on prognostic outcomes following radical nephrectomy.
Nishikawa M; Miyake H; Harada K; Fujisawa M
Urol Oncol; 2014 Jan; 32(1):49.e15-21. PubMed ID: 24239474
[TBL] [Abstract][Full Text] [Related]
18. Surgically induced ischemia has no impact on protein expression levels of HIF-1α and related biomarkers in renal cell carcinoma.
Mikkelsen ML; Marcussen N; Rabjerg M
APMIS; 2021 Sep; 129(9):535-547. PubMed ID: 33948984
[TBL] [Abstract][Full Text] [Related]
19. Caveolin-1 in renal cell carcinoma promotes tumour cell invasion, and in co-operation with pERK predicts metastases in patients with clinically confined disease.
Campbell L; Al-Jayyoussi G; Gutteridge R; Gumbleton N; Griffiths R; Gumbleton S; Smith MW; Griffiths DF; Gumbleton M
J Transl Med; 2013 Oct; 11():255. PubMed ID: 24119769
[TBL] [Abstract][Full Text] [Related]
20. Sunitinib, sorafenib and mTOR inhibitors in renal cancer.
Radulovic S; Bjelogrlic SK
J BUON; 2007 Sep; 12 Suppl 1():S151-62. PubMed ID: 17935273
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
